Audio

Samuel F. Hunter, MD, PhD

Publish date: June 4, 2015

An open-label study indicates that patients with multiple sclerosis may benefit from switching to alemtuzumab.

 

Recommended Reading

How Should Neurologists Treat Menopausal Women With MS?
ICYMI Multiple Sclerosis
Promoting MS Medication Adherence Through Telehealth
ICYMI Multiple Sclerosis
Variation in Brain Iron Levels in MS and CIS
ICYMI Multiple Sclerosis
Does Education Status Impact MS Risk?
ICYMI Multiple Sclerosis
Factors Linking Optic Neuritis to MS Risk
ICYMI Multiple Sclerosis
When Patients Don’t Respond to Interferon-β
ICYMI Multiple Sclerosis
Life Expectancy and Multiple Sclerosis
ICYMI Multiple Sclerosis
Switching From Natalizumab to Dimethyl Fumarate: Real-World Experience
ICYMI Multiple Sclerosis
Alemtuzumab May Suppress Disease Activity for Four Years
ICYMI Multiple Sclerosis
Daclizumab HYP May Improve Ambulation and Cognition, Compared With Interferon β-1a
ICYMI Multiple Sclerosis

Related Articles